These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36070391)

  • 1. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER
    Soria-Bretones I; Thu KL; Silvester J; Cruickshank J; El Ghamrasni S; Ba-Alawi W; Fletcher GC; Kiarash R; Elliott MJ; Chalmers JJ; Elia AC; Cheng A; Rose AAN; Bray MR; Haibe-Kains B; Mak TW; Cescon DW
    Sci Adv; 2022 Sep; 8(36):eabq4293. PubMed ID: 36070391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
    Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
    Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD63
    Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
    Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
    Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
    Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
    Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
    Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
    Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
    Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
    Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
    Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
    Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.
    Smith ER; Huang M; Schlumbrecht MP; George SHL; Xu XX
    Front Oncol; 2022; 12():907520. PubMed ID: 36185294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Res Sq; 2023 Jul; ():. PubMed ID: 37502925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
    Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review.
    Gao L; Shen X; He L; Wu J; Liu Y; Wang X; Shao X
    Ann Transl Med; 2022 Jan; 10(2):117. PubMed ID: 35282060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
    Al-Qasem AJ; Alves CL; Ehmsen S; Tuttolomondo M; Terp MG; Johansen LE; Vever H; Hoeg LVA; Elias D; Bak M; Ditzel HJ
    NPJ Precis Oncol; 2022 Sep; 6(1):68. PubMed ID: 36153348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
    Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
    Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.